Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1635 1637 1671 1682
This examiner grants 48% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17760504 | TARGETING RLIM TO MODULATE BODY WEIGHT AND OBESITY | Non-Final OA | University of Massachusetts |
| 19535829 | DNA COMPOSITIONS AND RELATED METHODS | Non-Final OA | FLAGSHIP PIONEERING INNOVATIONS VII, LLC |
| 17602150 | LONG-LASTING ANALGESIA VIA TARGETED IN VIVO EPIGENETIC REPRESSION | Non-Final OA | The Regents of the University of California |
| 17270832 | CATIONIC COMPOUNDS FOR DELIVERY OF NUCLEIC ACIDS | Final Rejection | The Regents of the University of California |
| 17059736 | RNA INTERFERENCE-INDUCING NUCLEIC ACID INHIBITING NONCANONICAL TARGETS OF MICRO RNA, AND USE FOR SAME | Non-Final OA | Korea University Research and Business Foundation |
| 17621029 | STRUCTURALLY DEFINED SIRNA-DUAL VARIABLE DOMAIN IMMUNOGLOBULIN CONJUGATES | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED |
| 18251514 | PRECISE GENOME DELETION AND REPLACEMENT METHOD BASED ON PRIME EDITING | Non-Final OA | University of Washington |
| 17800371 | AAV-Mediated Targeting of MIRNA in the Treatment of X-Linked Disorders | Final Rejection | UNIVERSITY OF VIRGINIA PATENT FOUNDATION |
| 18015202 | Circular siRNAs | Final Rejection | ALNYLAM PHARMACEUTICALS, INC. |
| 17974596 | APOLIPOPROTEIN E (APOE) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | Alnylam Pharmaceuticals, Inc. |
| 17611761 | ORAL DELIVERY OF OLIGONUCLEOTIDES | Final Rejection | ALNYLAM PHARMACEUTICALS, INC. |
| 17802789 | VEGFR-3-ACTIVATING AGENTS AND ONCOLYTIC VIRUSES AND USES THEREOF FOR THE TREATMENT OF CANCER | Final Rejection | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI |
| 18277023 | GENE THERAPY FOR DOPAMINE TRANSPORTER DEFICIENCY SYNDROME | Non-Final OA | UCL Business Ltd |
| 17284919 | The long non-coding RNA INCA1 and Homo sapiens heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) as therapeutic targets for immunotherapy | Final Rejection | The Brigham and Women`s Hospital, Inc. |
| 17628674 | REDUCTION OF BONE RESORPTION, ESPECIALLY IN CHRONIC JOINT DISEASES | Final Rejection | TECHNISCHE UNIVERSITÄT DARMSTADT |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy